 Neil Aggarwal
Concepts (300)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Outpatients | 5 | 2024 | 375 | 2.110 |
Why?
| | Oxygen | 8 | 2024 | 916 | 1.740 |
Why?
| | Acute Lung Injury | 11 | 2015 | 280 | 1.300 |
Why?
| | Macrophages, Alveolar | 5 | 2016 | 389 | 1.230 |
Why?
| | Pneumonia | 7 | 2025 | 619 | 1.070 |
Why?
| | Antiviral Agents | 4 | 2024 | 719 | 1.000 |
Why?
| | T-Lymphocytes, Regulatory | 5 | 2015 | 373 | 0.860 |
Why?
| | Hospitalization | 7 | 2024 | 2079 | 0.850 |
Why?
| | Interleukin-6 | 2 | 2024 | 724 | 0.740 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 6 | 2021 | 103 | 0.710 |
Why?
| | Oxygen Inhalation Therapy | 3 | 2024 | 145 | 0.700 |
Why?
| | Positive-Pressure Respiration | 1 | 2018 | 78 | 0.560 |
Why?
| | Phagocytes | 1 | 2018 | 97 | 0.540 |
Why?
| | Lung | 12 | 2018 | 3940 | 0.470 |
Why?
| | Smoke | 1 | 2016 | 140 | 0.470 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 546 | 0.470 |
Why?
| | Receptor, Adenosine A2A | 1 | 2013 | 20 | 0.410 |
Why?
| | Lipopolysaccharides | 9 | 2015 | 872 | 0.390 |
Why?
| | Immunity, Innate | 1 | 2018 | 804 | 0.380 |
Why?
| | Antibodies, Viral | 3 | 2024 | 602 | 0.370 |
Why?
| | Adult | 20 | 2025 | 35634 | 0.360 |
Why?
| | Antibodies, Monoclonal | 5 | 2024 | 1368 | 0.360 |
Why?
| | Lung Injury | 2 | 2011 | 211 | 0.350 |
Why?
| | Critical Illness | 5 | 2025 | 759 | 0.350 |
Why?
| | Mice, Inbred C57BL | 16 | 2025 | 5468 | 0.340 |
Why?
| | Hydroxychloroquine | 2 | 2020 | 55 | 0.340 |
Why?
| | Bacteria | 1 | 2016 | 814 | 0.330 |
Why?
| | Smoking | 2 | 2016 | 1502 | 0.320 |
Why?
| | Hypoxia | 4 | 2024 | 1087 | 0.320 |
Why?
| | Research Report | 2 | 2021 | 79 | 0.320 |
Why?
| | Respiratory Insufficiency | 2 | 2023 | 313 | 0.310 |
Why?
| | Intensive Care Units | 3 | 2025 | 738 | 0.310 |
Why?
| | Macrophages | 1 | 2016 | 1489 | 0.300 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2013 | 646 | 0.290 |
Why?
| | Humans | 43 | 2025 | 129847 | 0.290 |
Why?
| | Flow Cytometry | 3 | 2018 | 1160 | 0.290 |
Why?
| | Epithelial Cells | 4 | 2016 | 1063 | 0.280 |
Why?
| | Mice | 15 | 2025 | 16983 | 0.270 |
Why?
| | Vaccination | 2 | 2024 | 1348 | 0.270 |
Why?
| | Inflammation Mediators | 4 | 2016 | 505 | 0.270 |
Why?
| | Wound Healing | 1 | 2009 | 308 | 0.270 |
Why?
| | Critical Care | 2 | 2024 | 552 | 0.260 |
Why?
| | Mice, Knockout | 8 | 2015 | 2888 | 0.260 |
Why?
| | Male | 29 | 2025 | 63759 | 0.260 |
Why?
| | Carotid Artery, Internal | 1 | 2006 | 41 | 0.250 |
Why?
| | Immunophenotyping | 2 | 2018 | 310 | 0.250 |
Why?
| | Aged | 14 | 2025 | 22107 | 0.250 |
Why?
| | Carotid Artery Diseases | 1 | 2006 | 64 | 0.240 |
Why?
| | Sepsis | 2 | 2024 | 576 | 0.240 |
Why?
| | Phagocytosis | 2 | 2018 | 362 | 0.240 |
Why?
| | Animals | 19 | 2025 | 35409 | 0.230 |
Why?
| | Intracranial Aneurysm | 1 | 2006 | 95 | 0.230 |
Why?
| | Lymphopenia | 1 | 2025 | 60 | 0.230 |
Why?
| | Organ Dysfunction Scores | 1 | 2024 | 44 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2024 | 57 | 0.220 |
Why?
| | Respiration, Artificial | 3 | 2024 | 617 | 0.220 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 63 | 0.220 |
Why?
| | Lung Diseases | 2 | 2021 | 743 | 0.220 |
Why?
| | Multiple Organ Failure | 1 | 2024 | 123 | 0.210 |
Why?
| | Alanine | 1 | 2024 | 143 | 0.210 |
Why?
| | Biomedical Research | 2 | 2021 | 640 | 0.210 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 265 | 0.210 |
Why?
| | Middle Aged | 14 | 2025 | 31177 | 0.210 |
Why?
| | Antigens, Viral | 1 | 2024 | 179 | 0.210 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 49 | 0.210 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2024 | 122 | 0.200 |
Why?
| | Sleep Deprivation | 1 | 2025 | 171 | 0.200 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1686 | 0.200 |
Why?
| | Public-Private Sector Partnerships | 2 | 2021 | 42 | 0.200 |
Why?
| | Ritonavir | 1 | 2023 | 73 | 0.200 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 431 | 0.190 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2006 | 254 | 0.190 |
Why?
| | Intubation, Intratracheal | 1 | 2024 | 248 | 0.190 |
Why?
| | Acetaminophen | 1 | 2024 | 248 | 0.190 |
Why?
| | Cytokines | 3 | 2016 | 2022 | 0.180 |
Why?
| | Cell Membrane Permeability | 2 | 2012 | 82 | 0.180 |
Why?
| | Education | 1 | 2021 | 104 | 0.170 |
Why?
| | RNA, Viral | 1 | 2024 | 620 | 0.170 |
Why?
| | Pulmonary Alveoli | 3 | 2015 | 403 | 0.160 |
Why?
| | Tidal Volume | 2 | 2018 | 85 | 0.160 |
Why?
| | Neutrophils | 4 | 2015 | 1209 | 0.160 |
Why?
| | Antibodies | 1 | 2021 | 399 | 0.160 |
Why?
| | Triglycerides | 2 | 2013 | 528 | 0.160 |
Why?
| | Disease Models, Animal | 6 | 2025 | 4077 | 0.160 |
Why?
| | Machine Learning | 1 | 2024 | 441 | 0.160 |
Why?
| | Financing, Government | 1 | 2019 | 43 | 0.160 |
Why?
| | Serum Bactericidal Test | 1 | 2018 | 1 | 0.150 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 276 | 0.150 |
Why?
| | Rare Diseases | 1 | 2019 | 96 | 0.150 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2739 | 0.150 |
Why?
| | Interinstitutional Relations | 1 | 2018 | 53 | 0.150 |
Why?
| | Vascular Diseases | 1 | 2021 | 240 | 0.150 |
Why?
| | Pandemics | 3 | 2022 | 1500 | 0.150 |
Why?
| | Partial Pressure | 1 | 2018 | 30 | 0.150 |
Why?
| | Blood Gas Analysis | 1 | 2018 | 73 | 0.140 |
Why?
| | APACHE | 1 | 2018 | 65 | 0.140 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2018 | 85 | 0.140 |
Why?
| | Streptococcus | 1 | 2018 | 26 | 0.140 |
Why?
| | Female | 15 | 2025 | 68829 | 0.140 |
Why?
| | Endothelial Cells | 2 | 2016 | 749 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 252 | 0.140 |
Why?
| | Precision Medicine | 1 | 2021 | 385 | 0.140 |
Why?
| | Macrophage Activation | 1 | 2018 | 189 | 0.130 |
Why?
| | Cell Separation | 1 | 2018 | 316 | 0.130 |
Why?
| | Goals | 1 | 2018 | 163 | 0.130 |
Why?
| | Adoptive Transfer | 3 | 2015 | 218 | 0.130 |
Why?
| | Colorado | 2 | 2024 | 4410 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2018 | 334 | 0.130 |
Why?
| | Soot | 1 | 2016 | 25 | 0.130 |
Why?
| | Research | 1 | 2019 | 420 | 0.120 |
Why?
| | Chemokines | 2 | 2015 | 227 | 0.120 |
Why?
| | Lung Transplantation | 1 | 2018 | 290 | 0.120 |
Why?
| | Leukocytosis | 1 | 2015 | 31 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.120 |
Why?
| | Retrospective Studies | 5 | 2024 | 14553 | 0.120 |
Why?
| | DNA Modification Methylases | 1 | 2015 | 13 | 0.120 |
Why?
| | Muscular Atrophy | 2 | 2015 | 75 | 0.120 |
Why?
| | Wasting Syndrome | 1 | 2015 | 12 | 0.120 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2012 | 171 | 0.120 |
Why?
| | Epithelium | 1 | 2016 | 311 | 0.120 |
Why?
| | Tissue and Organ Procurement | 1 | 2018 | 290 | 0.110 |
Why?
| | Lipoprotein Lipase | 2 | 2013 | 59 | 0.110 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2015 | 157 | 0.110 |
Why?
| | Air Pollution, Indoor | 1 | 2016 | 141 | 0.110 |
Why?
| | Interleukin-10 | 2 | 2014 | 304 | 0.110 |
Why?
| | Societies, Medical | 1 | 2018 | 759 | 0.110 |
Why?
| | Muscle Proteins | 2 | 2015 | 222 | 0.110 |
Why?
| | Particulate Matter | 1 | 2016 | 247 | 0.110 |
Why?
| | Azacitidine | 1 | 2015 | 137 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2016 | 4102 | 0.110 |
Why?
| | Lipoproteins | 2 | 2013 | 172 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2015 | 121 | 0.110 |
Why?
| | Treatment Outcome | 6 | 2024 | 10241 | 0.100 |
Why?
| | Phenethylamines | 1 | 2013 | 23 | 0.100 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2013 | 21 | 0.100 |
Why?
| | Forkhead Transcription Factors | 2 | 2015 | 184 | 0.100 |
Why?
| | Bacteremia | 1 | 2015 | 194 | 0.100 |
Why?
| | Gene Knockout Techniques | 1 | 2013 | 109 | 0.100 |
Why?
| | United States | 8 | 2021 | 13913 | 0.100 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2022 | 20 | 0.100 |
Why?
| | Aquaporin 5 | 1 | 2012 | 2 | 0.100 |
Why?
| | Physical Conditioning, Animal | 1 | 2015 | 236 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 954 | 0.100 |
Why?
| | Air Pollutants | 1 | 2016 | 314 | 0.100 |
Why?
| | Time Factors | 5 | 2016 | 6550 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 827 | 0.090 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 2 | 1 | 2011 | 1 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1000 | 0.090 |
Why?
| | Adenosine | 1 | 2013 | 227 | 0.090 |
Why?
| | Capillary Permeability | 1 | 2011 | 141 | 0.090 |
Why?
| | Aftercare | 2 | 2023 | 206 | 0.090 |
Why?
| | Exercise Therapy | 1 | 2015 | 413 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2724 | 0.090 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 391 | 0.090 |
Why?
| | Treatment Failure | 2 | 2022 | 339 | 0.090 |
Why?
| | Genes, RAG-1 | 1 | 2009 | 12 | 0.080 |
Why?
| | HIV-1 | 1 | 2016 | 839 | 0.080 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2009 | 25 | 0.080 |
Why?
| | Microtubules | 1 | 2012 | 264 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2021 | 1897 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 82 | 0.080 |
Why?
| | Monocytes | 1 | 2012 | 554 | 0.080 |
Why?
| | Biomarkers | 2 | 2018 | 3971 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2009 | 326 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2009 | 483 | 0.070 |
Why?
| | Heart Failure | 1 | 2021 | 2148 | 0.070 |
Why?
| | Muscle, Skeletal | 2 | 2015 | 1644 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 756 | 0.070 |
Why?
| | Gene Regulatory Networks | 1 | 2009 | 280 | 0.070 |
Why?
| | Cohort Studies | 3 | 2024 | 5444 | 0.070 |
Why?
| | T-Lymphocyte Subsets | 1 | 2009 | 412 | 0.070 |
Why?
| | Adipose Tissue | 1 | 2011 | 594 | 0.070 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2011 | 279 | 0.070 |
Why?
| | Patient Discharge | 2 | 2023 | 856 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2025 | 148 | 0.060 |
Why?
| | Homeodomain Proteins | 3 | 2015 | 493 | 0.060 |
Why?
| | Receptors, CXCR4 | 2 | 2016 | 83 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2006 | 2511 | 0.050 |
Why?
| | Renal Replacement Therapy | 1 | 2024 | 87 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2545 | 0.050 |
Why?
| | Tripartite Motif Proteins | 2 | 2015 | 33 | 0.050 |
Why?
| | Masks | 1 | 2024 | 61 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 205 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2024 | 402 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1847 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2025 | 161 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 1058 | 0.050 |
Why?
| | Nucleocapsid | 1 | 2022 | 17 | 0.050 |
Why?
| | Electroencephalography | 1 | 2025 | 409 | 0.050 |
Why?
| | Angiopoietins | 2 | 2013 | 13 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 72 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 2012 | 139 | 0.050 |
Why?
| | Hemoglobins | 1 | 2024 | 339 | 0.050 |
Why?
| | Epigenomics | 1 | 2022 | 110 | 0.050 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2002 | 43 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1204 | 0.050 |
Why?
| | Health Policy | 1 | 2024 | 354 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2730 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2021 | 122 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 287 | 0.040 |
Why?
| | Random Allocation | 2 | 2012 | 347 | 0.040 |
Why?
| | User-Computer Interface | 1 | 2002 | 149 | 0.040 |
Why?
| | Macrophages, Peritoneal | 2 | 2012 | 92 | 0.040 |
Why?
| | Review Literature as Topic | 1 | 2021 | 66 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 3062 | 0.040 |
Why?
| | Prospective Studies | 3 | 2023 | 7158 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 131 | 0.040 |
Why?
| | Bronchoscopy | 1 | 2002 | 219 | 0.040 |
Why?
| | Antimalarials | 1 | 2020 | 30 | 0.040 |
Why?
| | Heart Arrest | 1 | 2024 | 323 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 374 | 0.040 |
Why?
| | Airway Obstruction | 1 | 2002 | 154 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 271 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1877 | 0.040 |
Why?
| | Sleep | 1 | 2025 | 689 | 0.040 |
Why?
| | Netherlands | 1 | 2018 | 77 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 231 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1005 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2022 | 615 | 0.030 |
Why?
| | Inflammation | 3 | 2015 | 2748 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2002 | 739 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2024 | 979 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 504 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 216 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 593 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 9801 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 234 | 0.030 |
Why?
| | Cognition | 1 | 2024 | 1125 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2016 | 0.030 |
Why?
| | Virus Diseases | 1 | 2018 | 210 | 0.030 |
Why?
| | Cell Count | 1 | 2016 | 318 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 514 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2016 | 135 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2018 | 433 | 0.030 |
Why?
| | Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2015 | 1 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 170 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2015 | 73 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2015 | 137 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 318 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 190 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 581 | 0.030 |
Why?
| | Sputum | 1 | 2016 | 302 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1434 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 332 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2016 | 309 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3397 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2015 | 199 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2015 | 146 | 0.030 |
Why?
| | Adipose Tissue, White | 1 | 2013 | 37 | 0.030 |
Why?
| | Benzylamines | 1 | 2012 | 41 | 0.030 |
Why?
| | Mice, Congenic | 1 | 2012 | 22 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2016 | 355 | 0.020 |
Why?
| | B7-2 Antigen | 1 | 2012 | 27 | 0.020 |
Why?
| | Heterocyclic Compounds | 1 | 2012 | 18 | 0.020 |
Why?
| | Cell Survival | 1 | 2016 | 1086 | 0.020 |
Why?
| | Adipose Tissue, Brown | 1 | 2013 | 51 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 79 | 0.020 |
Why?
| | RING Finger Domains | 1 | 2012 | 3 | 0.020 |
Why?
| | Diet, Atherogenic | 1 | 2011 | 6 | 0.020 |
Why?
| | Chylomicrons | 1 | 2011 | 9 | 0.020 |
Why?
| | Ventilators, Mechanical | 1 | 2011 | 56 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5085 | 0.020 |
Why?
| | Lipoproteins, VLDL | 1 | 2011 | 25 | 0.020 |
Why?
| | Myofibroblasts | 1 | 2012 | 121 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2695 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2011 | 90 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1465 | 0.020 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2011 | 58 | 0.020 |
Why?
| | Adenoviridae | 1 | 2011 | 193 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2011 | 238 | 0.020 |
Why?
| | Motor Activity | 1 | 2015 | 684 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 631 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2885 | 0.020 |
Why?
| | Trachea | 1 | 2011 | 231 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3269 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2008 | 0.020 |
Why?
| | Muscle Strength | 1 | 2012 | 304 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 528 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 590 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 12467 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1501 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1690 | 0.020 |
Why?
| | Fibroblasts | 1 | 2012 | 954 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2481 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2780 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7066 | 0.020 |
Why?
| | Adolescent | 1 | 2024 | 20451 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1708 | 0.010 |
Why?
| | Proteins | 1 | 2011 | 944 | 0.010 |
Why?
| | Survival Rate | 1 | 2009 | 1872 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2378 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2011 | 2703 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1368 | 0.010 |
Why?
| | Bronchography | 1 | 2002 | 10 | 0.010 |
Why?
| | Tracheal Stenosis | 1 | 2002 | 28 | 0.010 |
Why?
| | Blood Glucose | 1 | 2011 | 2103 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 314 | 0.010 |
Why?
| | Insulin | 1 | 2011 | 2330 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4935 | 0.010 |
Why?
|
|
Aggarwal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|